Literature DB >> 7541859

Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.

M S Soloway1, R Sharifi, Z Wajsman, D McLeod, D P Wood, A Puras-Baez.   

Abstract

PURPOSE: Nonrandomized clinical trials have suggested that preoperative androgen deprivation can decrease the likelihood of positive surgical margins in patients with clinically localized prostate cancer. A multicenter prospective randomized trial compared radical prostatectomy alone to radical prostatectomy after 3 months of leuprolide acetate depot and flutamide in patients with stage cT2bNxM0 prostate cancer and a serum prostate specific antigen level less than 50 ng./ml.
MATERIALS AND METHODS: We randomized 149 patients to undergo androgen deprivation and 138 to undergo lymphadenectomy with (137) or without (1) prostatectomy. Of the 154 patients randomized to the surgery alone group 144 underwent pelvic node dissection with (138) or without (6) prostatectomy.
RESULTS: There was no statistically significant difference between the 2 groups in operating time, blood loss, need for transfusion, postoperative morbidity or length of hospital stay. There were 4 rectal and 2 ureteral injuries in the surgery alone group and none in the pretreatment group (p < 0.05). Patients who received androgen deprivation preoperatively had a significantly lower rate of capsule penetration (47% versus 78%, p < 0.001), positive surgical margins (18% versus 48%, p < 0.001) and tumor at the urethral margin (6% versus 17%, p < 0.01).
CONCLUSIONS: Long-term followup data will be needed to determine whether there will be a lower incidence of biochemical relapse as determined by prostate specific antigen, local recurrence or metastasis, with an improvement in patient survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541859

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  43 in total

Review 1.  External beam radiation therapy: role of androgen deprivation.

Authors:  Patrick Kupelian
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

Review 2.  [Significance of neoadjuvant therapy before radical prostatectomy].

Authors:  R Paul; H Van Randenborgh; H Kübler; M Alschibaja; R Hartung
Journal:  Urologe A       Date:  2004-06       Impact factor: 0.639

3.  Reduction in physician reimbursement and use of hormone therapy in prostate cancer.

Authors:  Sean P Elliott; Stephanie L Jarosek; Timothy J Wilt; Beth A Virnig
Journal:  J Natl Cancer Inst       Date:  2010-12-03       Impact factor: 13.506

4.  Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Authors:  Robert W Ross; Matthew D Galsky; Phil Febbo; Marc Barry; Jerome P Richie; Wanling Xie; Fiona M Fennessy; Rupal S Bhatt; Julia Hayes; Toni K Choueiri; Clare M Tempany; Philip W Kantoff; Mary E Taplin; William K Oh
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

5.  Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.

Authors:  Xiao-Yong Pu; Xing-Huan Wang; Yi-Long Wu; Huai-Peng Wang
Journal:  J Cancer Res Clin Oncol       Date:  2007-04-25       Impact factor: 4.553

6.  Neoadjuvant Enzalutamide Prior to Prostatectomy.

Authors:  Bruce Montgomery; Maria S Tretiakova; Anthony M Joshua; Martin E Gleave; Neil Fleshner; Glenn J Bubley; Elahe A Mostaghel; Kim N Chi; Daniel W Lin; Martin Sanda; William Novotny; Kenneth Wu; Philip W Kantoff; Brett T Marck; Stephen Plymate; Steven P Balk; Peter S Nelson; Alvin M Matsumoto; Rosina T Lis; Adam Kibel; Gabriel P Haas; Andrew Krivoshik; Alison Hannah; Mary-Ellen Taplin
Journal:  Clin Cancer Res       Date:  2016-11-09       Impact factor: 12.531

7.  A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer.

Authors:  Claire Murphy; Lawrence True; Funda Vakar-Lopez; Jing Xia; Roman Gulati; Bruce Montgomery; Maria Tretiakova
Journal:  Prostate       Date:  2016-06-08       Impact factor: 4.104

8.  The effect of androgen deprivation on malignant and benign prostate tissue.

Authors:  P Guinan; D Didomenico; J Brown; M Shaw; R Sharifi; V Ray; S Shott; M Rubenstein
Journal:  Med Oncol       Date:  1997 Sep-Dec       Impact factor: 3.064

9.  Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.

Authors:  Jonathan L Silberstein; Stephen A Poon; Daniel D Sjoberg; Alexandra C Maschino; Andrew J Vickers; Aaron Bernie; Badrinath R Konety; W Kevin Kelly; James A Eastham
Journal:  BJU Int       Date:  2015-04-17       Impact factor: 5.588

10.  Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer.

Authors:  C Selli; R Montironi; A Bono; F Pagano; F Zattoni; A Manganelli; F P Selvaggi; G Comeri; G Fiaccavento; S Guazzieri; A Lembo; S Cosciani-Cunico; D Potenzoni; G Muto; R Mazzucchelli; A Santinelli
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.